Cell Care Research and TrialsWe are dedicated to supporting clinical trials in the use of umbilical cord blood in regenerative medicine applications. Prof Malhotra's STELLAR trial will review the feasibility and safety of administering autologous cord blood derived cells to newborn babies with antenatally diagnosed stroke (brain damage due to bleeding or lack of blood supply to a part of the brain).
Vital parameters, examinations and any adverse events in the first 48 hours after cell administration will be investigated to assess safety. As a secondary outcome looking at future larger trials, composite neurological and neurodevelopmental outcomes will be evaluated for 2 years.
Cell Care will be responsible for collection and release of umbilical cord blood cells for autologous administration to babies recruited to the trial.
We are dedicated to supporting preclinical studies and clinical trials in the use of umbilical cord blood in regenerative medicine applications. Dr Malhotra's Cord SaFe study will review the feasibility and safety of administering autologous cord blood of extreme premature infants (<28 weeks gestation).
Vital parameters, examinations and any adverse events in the first 48 hours after cell administration will be investigated to assess safety. As a secondary outcome looking at future larger trials, composite neurological and neurodevelopmental outcomes will be evaluated.
Cell Care will be responsible for release of umbilical cord blood cells for autologous administration to the extremely preterm babies recruited to the trial. Read more>>
Cell Care partnered with The Children’s Hospital at Westmead, New South Wales, in a world–first study investigating the potential of cord blood to prevent or delay the onset of type 1 diabetes (T1D) in children at high risk of developing the disease.
The CORD study recruited children between 1 and 14 years of age who were at high risk of developing T1D. Investigators expanded the recruitment to population screening - regardless of family history of type 1 diabetes. The study was available to families who have stored cord blood with a private cord blood storage company.
The CORD study has been approved by the Sydney Children's Hospitals Network Human Research Ethics Committee and is listed on the Australian and New Zealand Clinical Trial Register.
Cell Care supports research at the Monash Institute of Medical Research - Ritchie Centre, where scientists are investigating the underlying causes of newborn brain injury – which predominantly occurs either during pregnancy or at the time of birth. Their aim is to develop safe and effective therapies to prevent or repair brain injury, thereby reducing the incidence of cerebral palsy.
Read more about the Cell Care Senior Research Fellowship at The Ritchie Centre.